Breaking News Instant updates and real-time market news.

AAPL

Apple

, SCMP

Sucampo

$17.00

0.05 (0.29%)

09:17
12/26/17
12/26
09:17
12/26/17
09:17

On The Fly: Pre-market Movers

HIGHER: Sucampo Pharmaceutical (SCMP), up 5% after Mallinckrodt (MNK) announced a deal to acquire the company for $18.00 per share in a transaction with a value of approximately $1.2B. Mallinckrodt is up fractionally following Sucampo deal announcement... Organovo (ONVO), up 12% after the FDA granted orphan drug designation for the company's treatment of alpha-1 antitrypsin deficiency with its 3D bioprinted liver therapeutic tissue. LOWER: Apple (AAPL), down 2.7% after a Taiwanese newspaper report said the tech giant is trimming its first-quarter sales forecast, as highlighted by Bloomberg. Some notable Apple suppliers that are down following Bloomberg's report of weaker iPhone forecasts include Skyworks (SWKS), Cirrus Logic (CRUS), Broadcom (AVGO), Qorvo (QRVO), Finisar (FNSR) and Lumentum (LITE).

AAPL

Apple

SCMP

Sucampo

$17.00

0.05 (0.29%)

MNK

Mallinckrodt

SWKS

Skyworks

$97.07

-0.42 (-0.43%)

CRUS

Cirrus Logic

$52.38

-0.05 (-0.10%)

AVGO

Broadcom

$262.35

0.82 (0.31%)

QRVO

Qorvo

$67.69

0.21 (0.31%)

FNSR

Finisar

$21.39

-0.37 (-1.70%)

LITE

Lumentum

$52.80

-0.55 (-1.03%)

  • 09

    Jan

  • 09

    Jan

  • 27

    Feb

AAPL Apple

12/19/17
12/19/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying the stock's gains for the iPhone X "supercycle are in the late innings." 2. Hanesbrands (HBI) downgraded to Neutral from Buy at Citi with analyst Kate McShane saying the U.S. wholesale environment remains challenging due to declining traffic trends in stores and price-based competition in all channels. 3. PPL Corp. (PPL) downgraded to Underperform from Neutral at Macquarie with analyst Angie Storozynski saying she thinks the next UK regulatory review will result in a meaningful drop in revenues and believes the high dividend debate will come back into focus. 4. Chubb (CB) downgraded to Neutral from Outperform at Credit Suisse with analyst Ryan Tunis noting that while the integration of ACE Limited (ACE)/Chubb has been successful and positions the latter well for the future, the analyst argues that it is difficult for him to solve for much upside to medium term earnings per share and shares with the integration coming to a close in the fourth quarter. 5. KB Home (KBH) downgraded to Underweight from Neutral at JPMorgan with analyst Michael Rehaut citing valuation with the shares up 100% in 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/19/17
NOMU
12/19/17
DOWNGRADE
Target $175
NOMU
Neutral
Nomura downgrades Apple with share gains in 'late innings'
Nomura Instinet analyst Jeffrey Kvaal downgraded Apple to Neutral from Buy and cut his price target for the shares to $175 from $185. The iPhone maker closed yesterday up $2.45 to $176.42. The stock's gains for the iPhone X "supercycle are in the late innings," Kvaal tells investors in a research note. The analyst believes iPhone unit growth is well anticipated by consensus estimates and that Apple's multiple is now "historically full." Kvaal believes now is the time to downgrade the shares but admits Apple's "user base and services growth are powerful tailwinds."
12/21/17
MSCO
12/21/17
NO CHANGE
Target $200
MSCO
Overweight
iPhone X helping Apple accelerate share gains in China, says Morgan Stanley
Morgan Stanley analyst Katy Huberty said new data through the first 16 days of iPhone X availability in China show that adoption of the high-end device is on a faster pace than the iPhone 8 or 8 Plus, which she sees fueling an acceleration of Apple smartphone share gains. The analyst, who also noted that Google Trends data corroborate iPhone strength in China, said Apple remains her top pick entering 2018 and she keeps an Overweight rating on the stock with a $200 price target.
12/26/17
LSCM
12/26/17
NO CHANGE
LSCM
Buy
Lake Street says Knowles more likely than Himax to be impacted by Apple weakness
Lake Street analyst Jaeson Schmidt thinks Knowles (KN) is more likely to be impacted by concerns over iPhone X shipment weakness than Himax (HIMX), which is not immune but has the advantage of Android OEMs helping to backfill revenue that may be lost with Apple (AAPL). Amid the reports of concerns over weakness in first quarter iPhone X sales, he has Buy rating on the shares of both of the aforementioned Apple suppliers.
SCMP Sucampo
$17.00

0.05 (0.29%)

12/18/17
NOMU
12/18/17
INITIATION
Target $43
NOMU
Buy
Sucampo initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Sucampo with a Buy rating and $43 price target, stating that he believes its current valuation primarily reflects cash flows from its currently marketed drug, Amitiza, and neglects potentially newer pipeline products that could double revenues to $500M by 2020.
12/19/17
12/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Michael Kors (KORS) was initiated with a Buy at Needham while Tapestry (TPR) was initiated with a Hold. 2. Sherwin-Williams (SHW) initiated with a Strong Buy, named a Top Pick at Raymond James. 3. Sucampo (SCMP) initiated with a Buy at Nomura Instinet. 4. Semtech (SMTC) initiated with a Neutral at Piper Jaffray. 5. Mimecast (MIME) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
MAXM
12/07/17
NO CHANGE
Target $23
MAXM
Buy
Sucampo shares undervalued based on fundamentals, says Maxim
Following a Bloomberg report that said Sucampo may be entertaining suitors, Maxim analyst Jason Kolbert said this would be plausible given that the company's shares are undervalued, it is generating free cash flow and has a strong pipeline. However, he has no specific knowledge to confirm the report, Kolbert adds. He has a Buy rating and $23 price target on Sucampo shares.
11/14/17
RILY
11/14/17
INITIATION
Target $14
RILY
Buy
Sucampo initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started Sucampo Pharmaceuticals with a Buy rating and $14 price target.
MNK Mallinckrodt

11/22/17
OPCO
11/22/17
DOWNGRADE
OPCO
Perform
Mallinckrodt downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Mallinckrodt to Perform saying he's been "flat out wrong" on the shares. The thesis of branded growth and material margin expansion has not and is unlikely to play out within the next 12-18 months, Archila tells investors in a research note. He sees "little-to-no visibility" on Acthar growth outside of management's remarks on the payer pushback/patient abandonment issues. Further, Archila is not certain whether the company can remedy the Acthar growth issue in a timely manner. He pulled his price target for Mallinckrodt shares.
11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
LEHM
12/12/17
NO CHANGE
Target $23
LEHM
Equal Weight
Mallinckrodt management keeps conviction in Acthar, says Barclays
Barclays analyst Douglas Tsao says Mallinckrodt management in meetings last week reiterated their conviction in the Acthar franchise's durability. The analyst continues to believe the franchise should prove "reasonably durable," but after Q3's miss, he does not expect a "v-shaped" recovery next year. Further, Acthar,'s pressure could worsen if additional payers implement policies that affected Q3, Tsao tells investors in a research note titled "It always comes back to Acthar." The analyst keeps an Equal Weight rating on Mallinckrodt with a $23 price target.
12/22/17
WELS
12/22/17
NO CHANGE
WELS
Market Perform
Wells says tax act net effect seems positive for Mallinckrodt non-GAAP EPS
After Mallinckrodt released a regulatory filing this morning stating the company's anticipated puts and takes related to the passage of the U.S. Tax Cut and Jobs Act, Wells Fargo analyst David Maris said he believes the net effect of the TCJA seems positive for the company's non-GAAP EPS. Maris keeps a Market Perform rating on Mallinckrodt shares.
SWKS Skyworks
$97.07

-0.42 (-0.43%)

12/15/17
JPMS
12/15/17
NO CHANGE
JPMS
JPMorgan sees opportunities in Wireless Semiconductors, prefers Qorvo
JPMorgan analyst Bill Peterson believes the recent pullback in Wireless Semiconductor names, specifically Apple-exposed stocks, creates a good opportunity for investors to take long positions. The analyst sees the most upside in Qorvo (QRVO). He believes fears of production cuts and demand weakness are overblown. The December quarter and outlook for the March quarter are tracking to company expectations that have been built on conservative prospects for smartphone demand, Peterson tells investors in a research note.
12/20/17
PIPR
12/20/17
INITIATION
Target $115
PIPR
Overweight
Skyworks initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar started Skyworks Solutions with an Overweight rating and $115 price target. The analyst believes the company will continue to perform well in the mobile market over the near and medium term. Skyworks is well positioned to gain share and content in marquee handsets in both the U.S. and China, Kumar tells investors in a research note.
11/07/17
BOFA
11/07/17
NO CHANGE
Target $125
BOFA
Buy
Skyworks price target raised to $125 from $120 at BofA/Merrill
12/11/17
SBSH
12/11/17
NO CHANGE
SBSH
Citi 'getting more nervous' on semiconductors after Asia trip
Following a trip last week to Asia meeting with companies across the technology supply chain, Citi analyst Christopher Danely says he's "getting more nervous" on the semiconductor sector. While demand from the PC end market remains strong, the NAND market remains weak and data points on Apple's (AAPL) iPhone were mixed, Danely tells investors in a research note. The analyst saw signs of an inventory build and believes upside to consensus estimates is declining. He feels momentum is slowing in the semiconductor space. Danely's top pick is Microchip (MCHP) and he's also Buy-rated on Texas Instruments (TXN), Applied Materials (AMAT), Nvidia (NVDA), Skyworks (SWKS), ON Semiconductor (ON) and Micron (MU). The analyst's checks indicate slower than expected iPhone X and 8 demand but stronger iPhone 7 demand. He views this as bad for Skyworks and Qorvo (QRVO) and good for Analog Devices (ADI).
CRUS Cirrus Logic
$52.38

-0.05 (-0.10%)

09/18/17
09/18/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Teck Resources (TECK) initiated with a Sell at Axiom. 2. GenMark (GNMK) initiated with a Buy at BofA/Merrill. 3. Cirrus Logic (CRUS) initiated with an Underperform at BofA/Merrill. 4. Athenex (ATNX) initiated with an Outperform at Credit Suisse. 5. Brookfield Infrastructure (BIP) reinitiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/17
CHLM
09/21/17
NO CHANGE
CHLM
Customers waiting for Apple iPhone X with facial recognition, says Craig-Hallum
Craig-Hallum analyst Tony Stoss notes Apple (AAPL) suppliers sold off yesterday as order shipment dates for the iPhone 8/8 Plus remain relatively short for a new iPhone launch. The analyst thinks customers are waiting for the iPhone X with facial recognition. Stoss reiterates a Buy rating for Skyworks (SWKS), Broadcom (AVGO), Qorvo (QRVO), STMicroelectronics (STM), Cypress Semiconductor (CY), Knowles (KN) a Buy, and a Hold for Cirrus Logic (CRUS) and Synaptics (SYNA).
10/16/17
KEYB
10/16/17
NO CHANGE
KEYB
Apple supply chain to remain range-bound, says KeyBanc
KeyBanc analyst John Vinh says that because of supply constraints associated with the iPhone X, he anticipates Apple (AAPL) supply chain stocks will likely remain range-bound in the near term, given constraints make upside to estimates less likely, and constraints make it hard to assess true demand for the iPhone X. Additionally, his latest carrier survey indicates relatively lean iPhone 8 inventories despite muted demand and slightly higher demand for the iPhone 7. The analyst recommends investors continue to own Broadcom (AVGO), Cirrus Logic (CRUS), and Skyworks (SWKS).
11/06/17
KEYB
11/06/17
NO CHANGE
KEYB
Carrier surveys indicate strong demand, tight supply for iPhone X, says KeyBanc
KeyBanc analyst John Vinh says surveys at U.S. carriers on the iPhone X launch day and throughout the weekend indicate healthy initial response to Apple's (AAPL) new flagship model. Further, his surveys indicate most of the stores were sold out within a few hours after opening despite limited promotional activity. Supply was scarce as most T-Mobile (TMUS) and Sprint (S) stores indicated that they had not received any iPhone X shipments, and several AT&T (T) and Verizon (VZ) stores estimated they will need to wait until December before receiving additional shipments, he contends. Vihn's favorite Apple-related suppliers are Broadcom (AVGO), Cirrus Logic (CRUS), Cypress Semiconductor (CY), and Skyworks (SWKS).
AVGO Broadcom
$262.35

0.82 (0.31%)

12/15/17
OPCO
12/15/17
NO CHANGE
OPCO
Outperform
Broadcom Q2 estimate concerns overblown, says Oppenheimer
After meeting with management, Oppenheimer analyst Rick Schafer believes concerns over the Q2 estimates for Broadcom (AVGO) are overblown. The staggered launches of the two new iPhones creates near-term upside potential, Schafer tells investors in a research note. The company remains his top pick for 2018 with or without Qualcomm (QCOM). He keeps an Outperform rating on the shares with a $315 price target.
12/18/17
PIPR
12/18/17
INITIATION
Target $25
PIPR
Overweight
Marvell initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Harsh Kumar initiated Marvell with an Overweight rating and a price target of $25. Kumar says the company has "significant room to run in its turnaround", adding that its storage business will be a significant driver of growth. The analyst also contends that customers will seek an alternative in the Ethernet market and would welcome Marvell products to hedge those of Broadcom (AVGO). Kumar also believes the Cavium acquisition will bring cost synergies and added growth.
12/14/17
BNCH
12/14/17
NO CHANGE
BNCH
Buy
Xperi request to ITC may be signal of work on Broadcom license, says Benchmark
After Xperi's (XPER) Tessera division made a last minute request for the ITC to delay its release of its final determination in the company's patent complaint against Broadcom (AVGO), Benchmark analyst Gary Mobley said he thinks this may be related to an attempt to hash out a license agreement, perhaps at Broadcom's request. A license agreement would be a positive both because it would allow Xperi to achieve the high end of its Q4 revenue guidance but also because it could represent "the first domino to fall" with Samsung (SSNLF) and others, said Mobley, who keeps a Buy rating on Xperi shares.
12/18/17
CHLM
12/18/17
NO CHANGE
Target $40
CHLM
Buy
Xperi shares have room to rally further, says Craig-Hallum
Craig-Hallum analyst Richard Shannon believes Xperi's (XPER) settlement with Broadcom (AVGO) is "strong confirmation" of the company's process and intellectual property. Licensing Broadcom will drive other customers to license rather than litigate, Shannon tells investors in an intraday research note. He believes the upfront payment for Q4, which was not disclosed, is around $30M and that ongoing payments are likely extend around four years. Shannon sees a "multiplier effect" from the settlement and believes shares of Xperi have further room to run. The analyst has a Buy rating on the shares with a $40 price target. The stock in afternoon trading is up 9% to $25.78.
QRVO Qorvo
$67.69

0.21 (0.31%)

11/15/17
JPMS
11/15/17
NO CHANGE
Target $88
JPMS
Overweight
Qorvo shares remain undervalued, says JPMorgan
JPMorgan analyst Bill Peterson says that despite rallying 50% year-to-date, shares of Qorvo remain undervalued. The company's non-mobile, or Infrastructure and Defense Products, business continues to be underappreciated by investors, Peterson tells investors in a research note. He expects continued margin expansion and solid free cash flow generation and reiterates an Overweight rating on Qorvo with an $88 price target.
11/14/17
OTRG
11/14/17
NO CHANGE
OTRG
Qorvo may be running Galaxy Note8's high-band power amplifier, says OTR Global
FNSR Finisar
$21.39

-0.37 (-1.70%)

12/13/17
STFL
12/13/17
NO CHANGE
Target $26
STFL
Buy
Finisar price target raised to $26 after Apple award at Stifel
Stifel analyst Patrick Newton raised his price target for Finisar (FNSR) to $26 from $22 after the company announced it will receive $390M from Apple's (AAPL) Advanced Manufacturing Fund for building out its VCSEL production capabilities at its recently purchased Sherman facility. The analyst sees this as a win, and notes it further legitimizes 3D Sensing technology, eliminating any investor concern that Apple may revert to finger print sensors in the future as some data on iPhone X sell through has lagged expectations. He reiterates a Buy rating on Finisar's shares.
12/14/17
CHLM
12/14/17
NO CHANGE
Target $28
CHLM
Buy
Finisar price target raised to $28 after Apple award at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Finisar (FNSR) to $28 from $24 following Apple's (AAPL) award of $390M for VCSEL capacity/RD, which he believes is a "strong confirmation" of the market opportunity for 3D sensing, and a sign that the market is likely to be undersupplied for a number of quarters. The analyst reiterates a Buy rating on Finisar shares.
12/13/17
PIPR
12/13/17
NO CHANGE
Target $28
PIPR
Overweight
Finisar price target raised to $28 after Apple award at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target on Finisar (FNSR) to $28 from $22 after the company was awarded a $390M investment from Apple (AAPL) to scale VCSEL capacity, saying that he believes the deal solidifies a long-term relationship between the companies. Jensen has previously assumed Finisar only had 25% of the high-powered VCSEL for the iPhone X and Lumentum (LITE) had 75% of the high-power and 100% of the low-power VCSEL, but he now believes Finisar could capture significantly more share than previously expected, he tells investors.
12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Apple's investment in Finisar's new fab a neutral for Lumentum, says Rosenblatt
Rosenblatt analyst Jun Zhang said Apple's (AAPL) investment in Finisar's (FNSR) new fab is a neutral for Lumentum (LITE). Zhang said Finisar might not be able to supply the Android market as it sold all its potential capacity to Apple, reducing competition for Lumentum in that market. Further, the fab will take several quarters to prepare while the competitive landscape is not likely to change in 2018-2019, leaving Lumentum as the primary supplier to Apple, the analyst wrote.
LITE Lumentum
$52.80

-0.55 (-1.03%)

12/18/17
NEED
12/18/17
NO CHANGE
Target $80
NEED
Strong Buy
Lumentum is top 2019 idea in Optical and Networking, says Needham
Needham analyst Alex Henderson keeps his Strong Buy rating on Lumentum with a price target of $80. Henderson says the company's dominant market shares in its core ROADM and Pump Laser businesses distinguish it from competition in the optical space challenged with growth and pricing factors. The analyst says the company is his "Single Best Idea" in the Optical and Networking sector thanks to its mix of Optical fundamentals and "exceptional opportunity" in 3D.
12/20/17
RILY
12/20/17
NO CHANGE
Target $89
RILY
Buy
Lumentum to supply China Telecom's ROADM deployment, says B. Riley FBR
B. Riley FBR analyst Dave Kang says multiple Chinese media sources indicate that China Telecom (CHA) plans to deploy a ROADM-based network in both Northern and Southern China after successfully deploying a similar network in the middle and lower sections of the Yangtze River region. The analyst believes Lumentum (LITE) will be the primary supplier of ROADMs, or reconfigurable optical add/drop multiplexers. He points out the company's management recently indicated that several products, including ROADMs, have been expedited by Chinese customers. Further, Kang expects China Mobile (CHL) to follow China Telecom's lead, most likely in mid-2018. The analyst thinks the Chinese ROADM cycle will be an important catalyst for Lumentum in 2018 and beyond. The stock is up 11c to $53.51 in afternoon trading. Kang has a Buy rating on Lumentum with an $89 price target.
12/13/17
RSBL
12/13/17
NO CHANGE
RSBL
Lumentum weakness a buying opportunity, says Rosenblatt

TODAY'S FREE FLY STORIES

CBS

CBS

$51.75

0.14 (0.27%)

21:20
05/20/18
05/20
21:20
05/20/18
21:20
Upgrade
CBS rating change at Bernstein »

CBS upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight-Swift

$40.63

0.89 (2.24%)

20:40
05/20/18
05/20
20:40
05/20/18
20:40
Upgrade
Knight-Swift rating change at Stifel »

Knight-Swift upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

, FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

19:24
05/20/18
05/20
19:24
05/20/18
19:24
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

CBS

CBS

$51.75

0.14 (0.27%)

ROKU

Roku

$35.40

1.14 (3.33%)

LOW

Lowe's

$86.31

0.85 (0.99%)

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 22

    May

  • 23

    May

  • 12

    Jun

JHG

Janus Henderson Group

$32.43

-0.3 (-0.92%)

18:38
05/20/18
05/20
18:38
05/20/18
18:38
Hot Stocks
Janus Henderson Group announces dividend of 36c »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHG

Philips

$43.01

0.26 (0.61%)

17:29
05/20/18
05/20
17:29
05/20/18
17:29
Hot Stocks
New data shows combined COPD treatments could help reduce annual cost of care »

At the American Thoracic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWX

Time Warner

$94.26

1.37 (1.47%)

, CMCSA

Comcast

$32.72

0.3 (0.93%)

16:45
05/20/18
05/20
16:45
05/20/18
16:45
Hot Stocks
Box Office Battle: 'Deadpool 2' debuts at number 1 with $125M »

Ryan Reynolds and…

TWX

Time Warner

$94.26

1.37 (1.47%)

CMCSA

Comcast

$32.72

0.3 (0.93%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$48.60

-0.2 (-0.41%)

FOX

21st Century Fox

$37.27

-0.01 (-0.03%)

FOXA

21st Century Fox

$37.67

-0.08 (-0.21%)

LGF.A

Lionsgate

$24.27

0.3 (1.25%)

DIS

Disney

$103.94

-0.4 (-0.38%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

TSLA

Tesla

$276.84

-7.6 (-2.67%)

16:28
05/20/18
05/20
16:28
05/20/18
16:28
Periodicals
ISS recommending Tesla shareholders split chairman, CEO role, Bloomberg says »

The largest proxy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:23
05/20/18
05/20
16:23
05/20/18
16:23
Periodicals
China agrees to import more from U.S., no sign of $200B target, Reuters says »

China has agreed to…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$14.98

-0.05 (-0.33%)

, WAB

Wabtec

$95.23

1.1 (1.17%)

16:19
05/20/18
05/20
16:19
05/20/18
16:19
Periodicals
GE nearing deal to merge transportation unit with Wabtec, Reuters says »

General Electric (GE) is…

GE

General Electric

$14.98

-0.05 (-0.33%)

WAB

Wabtec

$95.23

1.1 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 12

    Jun

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, SPX

S&P 500

$0.00

(0.00%)

16:17
05/20/18
05/20
16:17
05/20/18
16:17
Periodicals
Trump administration walks back Chinese tariff plans, Axios says »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$77.47

0.965 (1.26%)

16:13
05/20/18
05/20
16:13
05/20/18
16:13
Hot Stocks
Dillard's announces 10c cash dividend »

Dillard's announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$6.45

-0.07 (-1.07%)

16:11
05/20/18
05/20
16:11
05/20/18
16:11
Hot Stocks
Data shows 'real-world' value of Afirma GSC in thyroid cancer diagnosis »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 12

    Jun

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

, MSCC

Microsemi

$68.60

(0.00%)

15:42
05/20/18
05/20
15:42
05/20/18
15:42
Conference/Events
Microsemi to host special shareholder meeting »

Special shareholder…

MCHP

Microchip

$92.80

-0.1865 (-0.20%)

MSCC

Microsemi

$68.60

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDNG

Hardinge

$18.44

0.03 (0.16%)

15:35
05/20/18
05/20
15:35
05/20/18
15:35
Conference/Events
Hardinge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBRG

Bravo Brio Restaurant

$4.05

(0.00%)

15:30
05/20/18
05/20
15:30
05/20/18
15:30
Conference/Events
Bravo Brio Restaurant to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/20/18
05/20
04:55
05/20/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

CBS

CBS

$51.75

0.14 (0.27%)

, VIA

Viacom

$33.80

-0.75 (-2.17%)

13:23
05/19/18
05/19
13:23
05/19/18
13:23
Periodicals
CBS looks like a bargain, Barron's says »

In a follow-up story,…

CBS

CBS

$51.75

0.14 (0.27%)

VIA

Viacom

$33.80

-0.75 (-2.17%)

VIAB

Viacom

$27.24

-0.92 (-3.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

, PEP

PepsiCo

$97.51

-0.45 (-0.46%)

13:10
05/19/18
05/19
13:10
05/19/18
13:10
Periodicals
Coca-Cola, PepsiCo look like bargains, Barron's says »

Investors have punished…

PG

Procter & Gamble

$73.45

-0.51 (-0.69%)

PEP

PepsiCo

$97.51

-0.45 (-0.46%)

KO

Coca-Cola

$42.18

-0.13 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$35.40

1.14 (3.33%)

10:32
05/19/18
05/19
10:32
05/19/18
10:32
Periodicals
Roku relevance worth taking note of, Barron's says »

Roku now is mostly a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

LOW

Lowe's

$86.31

0.85 (0.99%)

10:19
05/19/18
05/19
10:19
05/19/18
10:19
Periodicals
Lowe's turnaround what matters for long-term investors, Barron's says »

With Lowe's shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AAPL

Apple

$186.31

-0.69 (-0.37%)

, ZTCOY

ZTE Corp.

$0.00

(0.00%)

08:41
05/19/18
05/19
08:41
05/19/18
08:41
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$186.31

-0.69 (-0.37%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$32.97

0.45 (1.38%)

OCLR

Oclaro

$8.88

-0.015 (-0.17%)

TOSBF

Toshiba, also use TOSYY

$0.00

(0.00%)

TOSYY

Toshiba, also use TOSBF

$0.00

(0.00%)

GM

General Motors

$37.80

-0.51 (-1.33%)

F

Ford

$11.33

-0.12 (-1.05%)

FCAU

Fiat Chrysler

$21.86

-0.31 (-1.40%)

HMC

Honda

$32.98

-0.11 (-0.33%)

TM

Toyota

$136.04

-0.54 (-0.40%)

NSANY

Nissan

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

VRX

Valeant

$22.15

0.12 (0.54%)

PFE

Pfizer

$35.64

-0.07 (-0.20%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

INSY

Insys Therapeutics

$6.95

-0.37 (-5.05%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

BAYRY

Bayer

$0.00

(0.00%)

GILD

Gilead

$68.01

0.41 (0.61%)

BMRN

BioMarin

$88.95

0.51 (0.58%)

MNK

Mallinckrodt

$15.70

-0.37 (-2.30%)

SHPG

Shire

$169.62

-2.18 (-1.27%)

MRK

Merck

$59.13

0.06 (0.10%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

TEVA

Teva

$21.23

0.12 (0.57%)

AZN

AstraZeneca

$36.34

-0.09 (-0.25%)

ACOR

Acorda Therapeutics

$23.65

-0.45 (-1.87%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

NVS

Novartis

$77.08

-0.07 (-0.09%)

RHHBY

Roche

$0.00

(0.00%)

GALE

Galena

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 24

    May

  • 25

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

  • 22

    Aug

  • 27

    Aug

  • 07

    Sep

  • 10

    Sep

  • 12

    Sep

  • 05

    Oct

  • 23

    Oct

  • 13

    Nov

  • 20

    Dec

  • 21

    Dec

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.01

0.81 (0.36%)

04:55
05/19/18
05/19
04:55
05/19/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.01

0.81 (0.36%)

BIIB

Biogen

$280.35

-0.34 (-0.12%)

BSX

Boston Scientific

$30.46

0.13 (0.43%)

CELG

Celgene

$78.39

-1.59 (-1.99%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$51.10

-0.2 (-0.39%)

GSK

GlaxoSmithKline

$40.04

-0.06 (-0.15%)

HRC

Hill-Rom

$90.58

0.86 (0.96%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.58

-0.59 (-1.83%)

OCX

OncoCyte

$2.55

0.05 (2.00%)

VVUS

VIVUS

$0.79

0.1672 (26.78%)

NBRV

Nabriva Therapeutics

$5.43

0.25 (4.83%)

MYL

Mylan

$39.65

-0.45 (-1.12%)

MASI

Masimo

$97.11

0.34 (0.35%)

TEVA

Teva

$21.23

0.12 (0.57%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.60

2.55 (1.55%)

REGN

Regeneron

$301.87

-6.26 (-2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

SLDB

Solid Biosciences

$21.96

-0.79 (-3.47%)

18:46
05/18/18
05/18
18:46
05/18/18
18:46
Hot Stocks
Solid Biosciences announces new preclinical data for SGT-001 »

Solid Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

, USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

18:04
05/18/18
05/18
18:04
05/18/18
18:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.4K…

SPY

SPDR S&P 500 ETF Trust

$271.35

-0.66 (-0.24%)

USO

United States Oil Fund

$14.43

-0.06 (-0.41%)

GLD

SPDR Gold Trust

$122.42

0.06 (0.05%)

FXE

Euro Currency Trust

$113.01

-0.28 (-0.25%)

FXC

CurrencyShares Canadian Dollar Trust

$76.61

-0.38 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$114.04

0.11 (0.10%)

18:02
05/18/18
05/18
18:02
05/18/18
18:02
Hot Stocks
Celanese raises prices for emulsion polymers and acetyls »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.